Gilead Sciences Inc. announced Monday it is launching late-stage clinical trials of its “Quad” four-in-one HIV tablet. The company plans to run two studies. One will compare Quad with Gilead’s three-in-one HIV treatment Atripla; it will involve about 700 patients, run for 96 weeks, and take place at 130 sites in the United States and Puerto Rico. The other trial will compare Quad with the combination of Norvir, Reyataz, and Truvada; it will involve about 700 patients, run for 96 weeks, and take place at more than 200 sites in North and South America, Europe, and Asia Pacific. Quad contains elvitegravir, cobicistat, and the two elements of Truvada, emtricitabine and tenofovir. The newest component, cobicistat, is designed to boost blood levels of antiretrovirals like elvitegravir. Later this quarter, Gilead plans an additional study to compare cobicistat with Norvir. In that trial, patients will receive a combination of cobicistat, Truvada and Reyataz, or Norvir, Truvada and Reyataz.
Date of Publication
Antiretroviral Drugs Clinical Trials Combination Therapy HIV/AIDS Treatment or Therapies
Disclaimer: NPIN provides this information as a public service only. The views and information provided about the materials, funding opportunities, and organizations do not necessarily state or reflect those of the U.S. Department of Health and Human Services, CDC, or NPIN.